Researchers from University of California San Diego have found that two of the most frequently administered stem cell therapies, which are often used interchangeably, actually contain completely different types of cells. The results challenge the current “one-cell-cures-all” paradigm in orthopedic stem cell therapeutics and highlight the need for more informed and rigorous characterization of injectable stem cell therapies before they are marketed for use in patients.
Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called
December 11, 2023